| Literature DB >> 26931505 |
Ha Neul Kim1, Joon-Yong Jung2, Yeon Sik Hong1,3, Sung-Hwan Park1, Kwi Young Kang1,3.
Abstract
To determine the association between inflammatory and structural lesions on sacroiliac joint (SIJ) MRI and BMD and to identify risk factors for low BMD in patients with axial spondyloarthritis (axSpA). Seventy-six patients who fulfilled the ASAS axSpA criteria were enrolled. All underwent SIJ MRI and BMD measurement at the lumbar spine, femoral neck, and total hip. Inflammatory and structural lesions on SIJ MRI were scored. Laboratory tests and assessment of radiographic and disease activity were performed at the time of MRI. The association between SIJ MRI findings and BMD was evaluated. Among the 76 patients, 14 (18%) had low BMD. Patients with low BMD showed significantly higher bone marrow edema (BME) and deep BME scores on MRI than those with normal BMD (p < 0.047 and 0.007, respectively). Inflammatory lesions on SIJ MRI correlated with BMD at the femoral neck and total hip. Multivariate analysis identified the presence of deep BME on SIJ MRI, increased CRP, and sacroiliitis on X-ray as risk factors for low BMD (OR = 5.6, 14.6, and 2.5, respectively). The presence of deep BME on SIJ MRI, increased CRP levels, and severity of sacroiliitis on X-ray were independent risk factors for low BMD.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26931505 PMCID: PMC4773924 DOI: 10.1038/srep22158
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of axial spondyloarthritis patients with normal and low bone mineral density (Z score ≤ −2 at any site).
| Characteristic (N (%) or mean ± SD) | Patients with normal BMD (N = 62) | Patients with low BMD (N = 14) | |
|---|---|---|---|
| Age (years) | 33.4 ± 12.1 | 29.0 ± 10.4 | 0.266 |
| Male | 47 (76) | 14 (100) | 0.059 |
| Smoking, current | 20 (32) | 4 (29) | 1.000 |
| Alcohol excess | 5 (8) | 0 (0) | 0.577 |
| BMI, kg/m2 | 23.4 ± 3.8 | 23.4 ± 3.8 | 0.915 |
| Time from symptom onset (years) | 5.6 ± 8.4 | 5.3 ± 6.7 | 0.767 |
| Duration since diagnosis (years) | 1.7 ± 3.3 | 0.7 ± 1.9 | 0.244 |
| Family history of axSpA | 8 (13) | 1 (7) | 1.000 |
| HLA-B27 positive | 52 (84) | 14 (100) | 0.193 |
| Peripheral arthritis | 15 (24) | 4 (29) | 0.740 |
| Patient global assessment | 5.0 ± 2.2 | 5.6 ± 2.1 | 0.211 |
| BASDAI, score (range, 0–10) | 4.5 ± 2.1 | 4.7 ± 1.4 | 0.695 |
| BASFI, score | 2.0 ± 2.2 | 1.8 ± 1.2 | 0.637 |
| ASDAS-ESR | 2.7 ± 1.1 | 3.4 ± 0.7 | 0.026 |
| ASDAS-CRP | 2.5 ± 1.1 | 3.3 ± 0.8 | 0.008 |
| ESR, mm/h | 21.2 ± 20.7 | 37.5 ± 22.9 | 0.011 |
| CRP, mg/l | 9.2 ± 16.3 | 25.6 ± 26.4 | 0.002 |
| Bone alkaline phosphatase (U/l) | 25.6 ± 16.3 | 33.0 ± 14.1 | 0.092 |
| sCTX (ng/ml) | 0.4 ±0.4 | 0.4 ±0.3 | 0.485 |
| Grade of sacroiliitis on X-ray | 1.9 ± 1.0 | 2.7 ± 1.0 | 0.015 |
| mSASSS | 4.3 ± 14.2 | 8.9 ± 14.2 | 0.022 |
| Number of syndesmophytes | 1.5 ± 3.6 | 2.4 ± 5.1 | 0.653 |
| Patients on NSAIDs | 58 (95) | 14 (100) | 1.000 |
| Patients on sulfasalazine | 15 (25) | 4 (29) | 0.743 |
| Lumbar spine BMD, g/cm2 | 1.20 ± 0.16 | 0.90 ± 0.09 | <0.001 |
| Lumbar spine T score | 0.22 ± 1.32 | −2.4 ± 0.80 | <0.001 |
| Lumbar spine Z score | −0.08 ± 1.15 | −2.69 ± 0.44 | <0.001 |
| Femoral neck BMD, g/cm2 | 1.00 ± 0.15 | 0.87 ± 0.13 | 0.003 |
| Femoral neck T score | 0.31 ± 1.18 | −0.94 ± 1.03 | 0.001 |
| Femoral neck Z score | 0.26 ± 1.09 | −1.04 ± 0.83 | <0.001 |
| Total hip BMD, g/cm2 | 1.05 ± 0.15 | 0.90 ± 0.14 | 0.001 |
| Total hip T score | 0.75 ± 1.19 | −0.72 ± 1.27 | 0.001 |
| Total hip Z score | 0.64 ± 1.12 | −0.80 ± 1.03 | <0.001 |
BMD, bone mineral density; BASDAI, Bath AS Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; sCTX, serum cross-linked telopeptide of type-I collagen; mSASSS, modified Stokes Ankylosing Spondylitis Score; NSAIDs, nonsteroidal anti-inflammatory drugs.
Sacroiliac joint MRI findings in patients with axial spondyloarthritis (N = 76).
| MRI finding, (mean ± SD score) | Patients with normal BMD (N = 62) | Patients with low BMD (N = 14) | |
|---|---|---|---|
| Acute inflammation | |||
| Bone marrow edema (0–48) | 6.7 ± 8.1 | 10.1 ± 7.3 | 0.047 |
| Depth (0–12) | 1.3 ± 2.0 | 3.0 ± 2.6 | 0.007 |
| Intensity (0–12) | 0.8 ± 1.9 | 1.1 ± 1.8 | 0.196 |
| Total score (0–72) | 8.9 ± 10.9 | 14.4 ± 11.1 | 0.028 |
| Structural lesions | |||
| Fat metaplasia (0–40) | 3.2 ± 5.7 | 5.9 ± 10.8 | 0.238 |
| Erosion (0–40) | 4.8 ± 4.3 | 7.2 ± 5.1 | 0.086 |
| Backfill (0–20) | 2.0 ± 2.5 | 3.8 ± 3.7 | 0.074 |
| Ankylosis (0–20) | 0.6 ± 2.1 | 2.1 ± 5.1 | 0.197 |
| Total score (0–120) | 1.5 ± 9.7 | 19.0 ± 14.2 | 0.008 |
Correlation between acute inflammatory findings on sacroiliac joint MRI, inflammatory markers, bone turnover markers, and BMD in axSpA patients.
| Variable( | Acute inflammatory lesion on SIJ MRI | Inflammatory marker | ||||
|---|---|---|---|---|---|---|
| BME | Depth | Intensity | Total | ESR, mm/h | CRP, mg/l | |
| sCTX (ng/ml) | 0.266* | 0.309** | 0.131 | 0.283* | −0.156 | −0.121 |
| BALP (U/I) | −0.018 | −0.002 | −0.020 | 0.022 | −0.067 | 0.022 |
| Lumbar spine BMD, g/cm2 | −0.139 | −0.187 | −0.020 | −0.149 | −0.485** | −0.419** |
| Lumbar spine T score | −0.145 | −0.215 | −0.006 | −0.156 | −0.466** | −0.424** |
| Lumbar spine Z score | −0.136 | −0.212 | −0.071 | −0.146 | −0.419** | −0.394** |
| Femoral neck BMD, g/cm2 | −0.186 | −0.197 | −0.151 | −0.202 | −0.428** | −0.274* |
| Femoral neck T score | −0.249 | −0.243* | −0.160 | −0.235* | −0.393** | −0.260* |
| Femoral neck Z score | −0.218* | −0.298** | −0.183 | −0.287* | −0.456** | −0.202 |
| Total hip BMD, g/cm2 | −0.237* | −0.233* | −0.174 | −0.254* | −0.503** | −0.380** |
| Total hip T score | −0.268* | −0.205 | −0.190 | −0.233* | −0.456** | −0.360** |
| Total hip Z score | −0.341** | −0.330** | −0.233* | −0.345** | −0.419** | −0.309** |
BMD, bone mineral density; SIJ, sacroiliac joint; BME, bone marrow edema; FM, fat metaplasia; sCTX, serum cross−linked telopeptide of thpe-1 collagen; BALP, bone-specific alkaline phosphatase.
*p < 0.05, **p < 0.01.
Correlation between acute inflammatory findings on sacroiliac MRI, inflammatory markers, and total hip BMD (stratified according to symptom duration).
| Variable( | Acute inflammatory lesion | Inflammatory marker | |||
|---|---|---|---|---|---|
| BME | Depth | Intensity | ESR, mm/h | CRP, mg/l | |
| Sx. Duration ≤ 1 year (n = 35) | |||||
| Total hip BMD, g/cm2 | −0.307 | −0.438** | −0.052 | −0.513** | −0.385* |
| Total hip T score | −0.253 | −0.356* | −0.056 | −0.407* | −0.382* |
| Total hip Z score | −0.311 | −0.489** | −0.068 | −0.419* | −0.311 |
| Sx. Duration > 1 year (n = 41) | |||||
| Total hip BMD, g/cm2 | −0.079 | −0.003 | −0.003 | −0.517** | −0.347* |
| Total hip T score | −0.164 | −0.099 | −0.099 | −0.501** | −0.311 |
| Total hip Z score | −0.208 | −0.136 | −0.120 | −0.443** | −0.270 |
BMD, bone mineral density; SJI, sacroiliac joint; BME, bone marrow edema.
*p < 0.05, **p < 0.01.
Figure 1Correlation between depth scores for bone marrow edema on sacroiliac MRI and the total hip BMD Z score.
The bone marrow edema depth scores on SIJ MRI correlated with the total hip Z score for the normal ESR group (n = 43) (A), but not with that for the elevated ESR group (n = 33) (B).
Univariate and multivariate logistic regression analysis of low BMD (Z score ≤ −2 at any site).
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Presence of BME | 6.2 (0.8–50.7) | 0.089 | ||
| Presence of depth | 5.4 (1.4–21.4) | 0.016 | 5.6 (1.1–27.9) | 0.036 |
| Increased ESR (≥20 mm/hr) | 6.7 (1.7–26.5) | 0.007 | ||
| Increased CRP (≥5 mg/l) | 13.6 (2.8–66.7) | 0.001 | 14.6 (2.5–85.0) | 0.003 |
| Grade of sacroiliitis on X-ray | 2.3 (1.2–4.4) | 0.018 | 2.5 (1.1–5.8) | 0.036 |
| mSASSS (≥2) | 3.8 (1.1–12.8) | 0.032 | ||
OR, odds ratio; CI, confidence interval; BME, bone marrow edema; mSASSS, modified Stokes Ankylosing Spondylitis Score.